CompuFlo® Epidural System becoming accepted as best-in-class for measuring tissue density and needle location in real time
LIVINGSTON, N.J., July 03, 2018 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that the CompuFlo® Epidural System was selected to objectively measure the integrity of a third-party, high fidelity epidural simulator in real time and was featured in a research article entitled, “Objective Evaluation of a New Epidural Simulator by the CompuFlo® Epidural Instrument,” in Anesthesiology Research and Practice, a peer-reviewed journal that provides a forum for health care professionals engaged in perioperative medicine, critical care, and pain management. The study was conducted at the European School of Obstetric Anesthesia (EESOA), Maternal Neonatal Simulation Centre, in Rome, Italy by Giorgio Capogna, Alessandra Coccoluto, Emanuele Capogna, and Angelica Del Vecchio. The full article is available at: https://www.hindawi.com/journals/arp/2018/4710263/
Mark Hochman, D.D.S., Director of Clinical Affairs for Milestone Scientific, commented, “The CompuFlo® Epidural System continues to receive positive feedback from key opinion leaders world-wide. The fact that the CompuFlo® Epidural System was selected to objectively measure and evaluate the integrity of a third-party epidural simulator, in connection with a published research article, further illustrates that CompuFlo® is becoming accepted as best-in-class for its ability to measure tissue density and accurately identify the tip of the needle in real time. We are pleased to have the CompuFlo® Epidural System featured in a prominent peer-reviewed scientific journal.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]